(Press-News.org)
A recent study led by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona has identified a new biomarker for Alzheimer's disease in asymptomatic stages of the disease. The molecule is miR-519a-3p, a microRNA directly linked to the expression of the cellular prion protein (PrPC), which is deregulated in people suffering from some neurodegenerative diseases such as Alzheimer's.
The search for biomarkers that are stable and easily detectable in biofluids, such as microRNAs, offers hope for detecting Alzheimer's disease in its early, asymptomatic stages. Early detection could significantly improve the diagnosis and treatment of this disease, which affects more than 35 million people worldwide.
First link between miR-519a-3p and PrPC in Alzheimer's disease
The expression of some microRNAs is known to be deregulated in Alzheimer's patients. However, this is the first time that this microRNA has been specifically linked to the decrease in cellular prion protein production during disease progression.
“Currently, tests to diagnose Alzheimer's disease are usually carried out after the onset of symptoms, when there is already underlying cognitive impairment. We believe that the detection of this microRNA may help to establish additional criteria for a more accurate diagnosis in the early stages of the disease,” explains IBEC principal investigator José Antonio del Río, full professor at the Faculty of Biology and the Institute of Neurosciences of the University of Barcelona (UB) and co-leader of the study.
The study also comparatively analyses the presence of the biomarker in samples from other neurodegenerative diseases:
If our goal is to use miR-519a-3p as a biomarker to detect Alzheimer's dementia in hypothetically healthy people, it is essential to ensure that its levels are not altered in other neurodegenerative diseases. In our study, we compared the levels of this biomarker in samples from other tauopathies and Parkinson's disease, confirming that the changes in miR-519a-3p are specific to Alzheimer's disease," said IBEC senior researcher Rosalina Gavín, UB associate professor and co-leader of the study.
Dayaneth Jácome, a researcher in del Río's group and first author of the study, says that the team is making progress: The next step is to validate miR-519a-3p as a biomarker in blood samples from different cohorts of patients, in order to start using it in the clinical diagnosis of Alzheimer's disease in peripheral samples.
The researchers are members of the Center for Networked Biomedical Research in Neurodegenerative Diseases, CIBERNED.
MicroRNAs: gene silencers
The amount of cellular prion protein changes over the course of Alzheimer's disease, with higher levels in the early stages of the disease and lower levels as the disease progresses. Although the mechanism responsible for these changes is not known in detail, it has been observed that certain microRNAs bind to a specific region of the PRNP gene that controls PrPC expression, reducing it. For this reason, and based on comparisons of previous studies and computational analyses in various genomic databases, the researchers selected the microRNA miR-519a-3p for their study.
END
New research has shed light in the complex interplay between cell proteins, and how they impact on neurons in neurodevelopmental disorders and Alzheimer’s disease.
A new study led by the University of Exeter and published in Royal Society Open Biology has discovered the key role that the protein Contactin-4 (encoded by the gene CNTN4) plays in shaping neurons.
The researchers began studying CNTN4 because it was known to have a role in autism, but its functional roles were not well understood. The team explored how CNTN4 functions within the brain, particularly its interactions with proteins involved in neurodegenerative diseases like Alzheimer's ...
Lifespan caps for passenger vehicles have limited effect on reducing greenhouse gas emissions and could drive up costs and material use finds a new study published in Environmental Research: Infrastructure and Sustainability. The research shows that although Light-Duty vehicles (LDVs) contribute 17% to the annual greenhouse gas emissions in the United States, imposing a 15-year lifespan cap on LDV fleets under a business-as-usual scenario will not lead to any meaningful reductions in GHG emissions.
To combat delayed uptake of Electric Vehicles (EVs), some have argued for limits on the vehicle’s ...
Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice. Among them is the NOTION-2 randomised clinical trial (RCT).
Background
Evidence comparing the use of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in low-risk patients with aortic ...
Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice. Among them is the REC-CAGEFREE II trial.
Background and methods
The REC-CAGEFREE II trial is an open-label, investigator-initiated, non-inferiority, multicentre randomised trial comparing stepwise de-escalation of dual antiplatelet therapy (DAPT) with standard DAPT in patients with acute coronary syndrome (ACS) treated with paclitaxel-coated balloons (PCB). Eligible ...
Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice. Among them is the LANDMARK trial.
Background and Methods
Key randomized controlled trials have compared surgical aortic valve replacement (SAVR) with transcatheter aortic valve implantation (TAVI) using one of two commercially available transcatheter heart valves (THVs) - ...
New research published in Aging Cell provides insights into how exercise may help to prevent or slow cognitive decline during aging.
For the study, investigators assessed the expression of genes in individual cells in the brains of mice. The team found that exercise has a significant impact on gene expression in microglia, the immune cells of the central nervous system that support brain function. Specifically, the group found that exercise reverts the gene expression patterns of aged microglia to patterns seen in young microglia.
Treatments that depleted ...
Gelatinous zooplankton, including jellyfish and other diverse, nearly transparent organisms, play important roles in marine ecosystems. Climate change is expected to significantly alter their populations and distributions. New research published in Limnology and Oceanography examines their fate in the Arctic Ocean, one of the fastest warming oceans on Earth.
Investigators coupled three-dimensional species distribution models with oceanographic variables from the Coupled Model Intercomparison Project Phase 6. The analyses allowed the team to identify gelatinous ...
A protein called retinitis pigmentosa GTPase regulator interacting protein 1-like (RPGRIP1L) performs various functions that are important for development and for health throughout life, and mutations in the RPGRIP1L gene have been linked to different diseases. New research published in The FASEB Journal indicates that expression levels of the RPGRIP1L gene might serve as a new prognostic marker for individuals with invasive breast cancer.
When investigators examined breast tissue specimens from different women, they found that the ...
A new study published in the Journal of Computer Assisted Learning introduces a novel Robot-Inspired Computer-Assisted Adaptive Autism Therapy (RoboCA3T) that leverages the natural affinity of children with autism spectrum disorder towards technology and robots.
RoboCA3T harnesses the potential of robot-assisted therapies by incorporating robot avatars and integrating them with computer-assisted therapies through a web-based solution.
When investigators assessed Childhood Autism Rating Scale scores before and after the intervention, ...
The extent of individuals’ mobility within their community—how much they get out and about—may be linked to their cognitive function, according to new research published in the Journal of the American Geriatrics Society.
In the study of 7,016 Black and white adults aged 52 years and older who completed various questionnaires, greater community mobility was significantly associated with better cognitive function, although the association was small.
Because higher atherosclerotic cardiovascular disease (ASCVD) risk is associated with both mobility limitations and cognitive decline, investigators ...
